Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
60%
Ph not_applicable
1
20%
Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(3)
Other(2)

Detailed Status

Completed3
unknown2

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (20.0%)
Phase 33 (60.0%)
N/A1 (20.0%)

Trials by Status

unknown240%
completed360%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

NCT05107375
completedphase_1

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

NCT04961359
unknownphase_3

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

NCT04646590
unknownphase_3

Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)

NCT05091411
completednot_applicable

Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity

NCT05089045

Clinical Trials (5)

Showing 5 of 5 trials
NCT05107375Phase 3

Clinical Study of Recombinant Novel Coronavirus（COVID-19） Vaccine (CHO Cell) Combined With Influenza Vaccine

Completed
NCT04961359Phase 1

Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2（COVID-19） Phase I Clinical Trial (3~17 Years Old)

Completed
NCT04646590Phase 3

A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19

Unknown
NCT05091411Phase 3

Clinical Trials of the Consistency and Non-inferiority Bridging Between Batches of Recombinant New Coronavirus Vaccine (CHO Cells)

Unknown
NCT05089045Not Applicable

Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5